Hikma Pharmaceuticals Plc Hikma reaches licensing agreement with Celltrion

TIDMHIK

Hikma Pharmaceuticals Plc

19 December 2017

PRESS RELEASE

Hikma reaches licensing agreement with Celltrion for third biosimilar product in the Middle East and North Africa

London, 19 December 2017 - Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody's / BB+ S&P, both stable) announces that it has reached a licensing agreement with South Korea-based Celltrion, Inc. and Celltrion Healthcare, Inc (Celltrion) for the first biosimilar monoclonal Antibody (mAb) in oncology to be granted European marketing authorisation, Truxima(TM) (rituximab). Hikma now has exclusive agreements with Celltrion for three biosimilar products - Truxima(TM) (rituximab), Remsima(R) (infliximab) and Herzuma(R) (trastuzumab) - in all its MENA markets.

Truxima(TM) is mAb biosimilar to Roche's MabThera(R) (rituximab), which is used to treat patients with non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis.

Under the terms of the agreement, Hikma has the exclusive rights to distribute and market Truxima(TM) (rituximab) in all of its MENA markets, leveraging Hikma's strong local presence, biosimilar expertise, sales and marketing capabilities and regulatory expertise.

Mazen Darwazah, Vice Chairman and CEO of MENA and Emerging Markets said, "We are pleased to be adding Truxima(TM) to our biosimilar and oncology portfolio, building on the success of our partnership with Celltrion in the MENA region. Global partnerships are an integral part of our strategy to enhance our portfolio in key therapeutic areas and increase patients' access to high-quality, affordable medicines."

Enquiries

Hikma Pharmaceuticals PLC

 
 Susan Ringdal 
  VP Corporate Strategy and         +44 (0)20 7399 2760/ 
  Director of Investor Relations     +44 7776 477050 
 Virginia Spring                    +44 (0)20 3892 4389/ 
  Investor Relations Manager         +44 7973 679502

FTI Consulting

 
 Ben Atwell/Brett Pollard    +44 (0)20 3727 1000

About Hikma

Hikma Pharmaceuticals PLC is a multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: 'Injectables,' 'Generics' and 'Branded,' based primarily in the Middle East and North Africa (MENA) region, where it is a market leader, the United States and Europe. In 2016, Hikma achieved revenues of $1,950 million and profit attributable to shareholders of $155 million.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAGGGGAPUPMGPR

(END) Dow Jones Newswires

December 19, 2017 04:00 ET (09:00 GMT)

Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024